


Key Information and Investment Disclosure Statement As of August 30, 2024



e vision

FUND FACTS							
Classification:		Equity Feeder Fund	NAVPU:	USD 105.03			
Launch Date:		February 1, 2021	Total Fund NAV (Mn):	USD 5.01			
Minimum Inves		USD 100.00	Dealing Day:	Daily up to 2:00 PM			
Additional Inve		No minimum	Redemption Settlement:	T+5 End-of-Day			
Minimum Hold	ing Period:	None	Early Redemption Charge:	None			
FEES Trustee Fees:	0 10700/ *	Custodianship Fee: 0.0000	% External Audit Fee: 0.0000%	** Other Fees: 0.0138%***			
1.50% per annu		Custodianship ree. 0.0000	External Addit Fee. 0.0000%	Other Fees. 0.0136%			
-		Nono		Index Licensing Fee			
BPI Wealth       None       Isla Lipana       Index Licensing Fee         *Monthly rate: Billings received for August 2024 divided by the average daily NAV for the same month valued at USD 5.21 Mn         **Billing is received at the last quarter of the year         ***Billings received in August 2024							
INVESTMENT (	<b>OBJECTIVE</b>	AND STRATEGY					
The Fund, operating as a Feeder Fund, intends to achieve long term capital growth by investing in a Target Fund that invests in stocks in the health care sector. The Fund aims to provide excess return over the MSCI World Health Care Index. Pursuant to existing BSP rules and regulations, as a Feeder Fund, this Fund is mandated to invest at least 90% of its assets in a single collective investment scheme.							
CLIENT SUITA	BILITY						
<ul> <li>A client profiling process shall be performed prior to participating in the Fund to guide the prospective investor if the Fund is suited to his/her investment objectives and risk tolerance. Clients are advised to read the Declaration of Trust/Plan Rules of the Fund, which may be obtained from the Trustee, before deciding to invest.</li> <li>The BPI Global Health Care Feeder Fund is for investors who: <ul> <li>Are at least classified as aggressive based on their risk profile.</li> <li>Have an investment horizon of at least five (5) years.</li> </ul> </li> </ul>							
Participation in the Fund shall be open to Participants with legal capacity to contract and who are not considered US persons under the US securities and tax laws, subject to the other conditions, rules or provisions stated in the Plan Rules and those established by the Trustee. No beneficial owner shall hold more than 10% of the Fund. Any investor who owns more than 10% shall be asked to redeem the amount (or its equivalent number of units) in excess of 10% within thirty (30) calendar days.							
KEY RISKS AN			or are not comfortable with the acce	mponying ricko			
		,	or are not comfortable with the acco in the prices of global equities in the	1 7 8			
Market/Price Risk:	adverse mar political and	ket conditions, unfavorable con economic conditions of the foc	mpany earnings and valuations, and cus countries of the securities of the	I negative developments in the target fund.			
Liquidity Risk:	Investors are exposed to the risk of loss due to the target fund's inability to convert security holdings to cash <b>lity Risk:</b> immediately or in instances where conversion to cash is possible but at a highly disadvantageous price due to limited participants in the market, low trading volumes, market disruptions, among others.						
Country Risk:	Investors are exposed to the risk of loss arising from negative developments in the political, economic and untry Risk: social conditions of the focus countries of the underlying securities of the target fund, which may adversely affect the value of the feeder fund.						
FX Risk:	value of forei	ign currency denominated sec	om a decline in the market value of the urities held by the target fund are tra	anslated to USD.			
The Fund's investment outlets undergo proper screening and evaluation in accordance with the Trustee's accreditation process. The Fund may also use financial derivatives to hedge the portfolio against market and credit risks.							
<ul> <li>THE UIT FUND IS NOT A DEPOSIT AND IS NOT INSURED BY THE PHILIPPINE DEPOSIT INSURANCE CORP. (PDIC).</li> <li>RETURNS CANNOT BE GUARANTEED AND HISTORICAL NAVPU IS FOR ILLUSTRATION OF NAVPU MOVEMENTS/ FLUCTUATIONS ONLY.</li> </ul>							
• WHEN REDEEMING, THE PROCEEDS MAY BE WORTH LESS THAN THE ORIGINAL INVESTMENT AND ANY LOSSES SHALL BE SOLELY FOR THE ACCOUNT OF THE CLIENT.							
<ul> <li>THE TRUSTEE IS NOT LIABLE FOR ANY LOSS UNLESS UPON WILLFUL DEFAULT, BAD FAITH OR GROSS NEGLIGENCE.</li> <li>THIS PRODUCT CANNOT BE SOLD TO YOU UNLESS ITS BENEFITS AND RISKS HAVE BEEN THOROUGHLY EXPLAINED. IF YOU DO NOT FULLY UNDERSTAND THIS PRODUCT, DO NOT PURCHASE OR INVEST IN IT.</li> </ul>							

FUND PERFORMANCE AND STATISTICS AS OF AUGUST 30, 2024									
(Purely for reference purposes and is not a guarantee of future results)           NAVPU GRAPH         NAVPu over the past 12 months									
	п						NAVPu over the past 12 months	105.03	
130					m	<b>M</b>	Highest		
115	who who	A. Ale	$\sim$	m	Lowest	79.73			
100							STATISTICS		
85							Volatility, since inception (%) <sup>4</sup>	13.53	
70		Benchmark					Sharpe Ratio <sup>5</sup>	1.02	
Jul-21 M	ar-22	Oct-22	Jun-2	23 Ja	an-24	Aug-24	Information Ratio <sup>6</sup>	-0.19	
*MSCI World Health Care Index <sup>1</sup> Returns are net of fees.									
CUMULATIVE PERFORMANCE (%) <sup>1</sup> <sup>2</sup> Since Inception									
		3 mos		1YR	3YRS	S.I. <sup>2</sup>	<sup>3</sup> Fund performance from Feb to year-en <sup>4</sup> Measures the degree to which the Fund		
Fund	5.25	10.83	10.33	19.23	2.48	5.03	vis its average return over a period of tim		
Benchmark	5.49	11.00	12.04	20.50	18.05	36.39	<sup>5</sup> Used to characterize how well the retur		
ANNUALIZED					EVD.	012	compensates the investor for the level of	risk taken. The	
-	1YR	2YRS	3YRS	4YRS	5YR	S.I. <sup>2</sup>	higher the number, the better.		
Fund Benchmark	<b>19.23</b> 20.50	<b>12.46</b> 15.18	<b>0.82</b> 5.69	-	-	<b>1.38</b> 9.06	<sup>6</sup> Measures reward-to-risk efficiency of the		
CALENDAR Y					-	9.06	relative to the benchmark. The higher the higher the reward per unit of risk.	e number, the	
CALENDAR T	YTD	2023	2022	<b>202</b> 1 <sup>3</sup>			nigher the reward per drift of fisk.		
Fund	14.72	4.37	-11.52	-0.86					
Benchmark	17.64	3.33	-5.02	18.13					
PORTFOLIO C	OMPOSI						*D	a satul as al	
Allocation					% of F	und	*Declaration of Trust is available upon request through your branch of account.		
Target Fund 98.72						2	TOP TEN HOLDINGS		
Cash and Equivalents 10.90									
Others – net of liabilities -9.62				2		of Target Fund			
Regional Brea	akdown			%	6 of Targ		Eli Lilly & Co	9.05	
United States					71.0		UnitedHealth Grp Inc	7.04	
United Kingdom 7.20						Novo Nordisk A/S	5.38		
Denmark					6.83		AstraZeneca PLC	4.32	
Others 14.93						Merck & Co Inc	4.09		
Sector Breako					% of Targ		Novartis AG	2.76	
Major Pharmaceuticals 25.91				Danaher Corp	2.63				
Biotechnology19.39Health Services15.57				Bos Scientific Corp	2.50				
Health Services15.57Medical Technology12.40				Intuitive Surgical	2.19				
Others         26.73			Argenx SE	2.19					
RELATED PARTY TRANSACTIONS*							<u> </u>		
	The Fund has transactions and outstanding investments with entities related to BPI Wealth – A Trust Corporation ("BPI Wealth").							BDI Wealth")	
The Fund has transactions and outstanding investments with entities related to BPI wealth – A Trust Corporation ("BPI wealth").									

Bank of the Philippine Islands - USD0.50 Mn

\* Related party in accordance with BPI Wealth's internal policy.

OTHER FUND FACTS								
Fund Currency:	US Dollar	Fund structure:	UCITS (IRL)					
Benchmark*:	MSCI World Health Care Index	Inception Date:	October 31, 2003					
Name of Target Fund:	Wellington Global Health Care Equity Fund	Custodian:	State Street Custodial Services (Ireland) Limited					
Regulator:	Central Bank of Ireland	Total Expense Ratio:	1.32%					
Fund Manager:	Wellington Management Company LLP							

The Fund Performance Report and relevant information about the Wellington Global Health Care Equity Fund can be viewed and downloaded through https://www.wellingtonfunds.com/en-at/institutional/.

## **OUTLOOK AND STRATEGY**

**Market Review.** Global equities posted positive returns in August with the MSCI All Country World Index returning 2.6%. In the US, the S&P 500 declined as much as 7.0% at the beginning of the month amid weak economic data as July non-farm posted 114,000 jobs, significantly below the expected 175,000 jobs, and the unemployment rate rose to 4.3%. Later in the month, more reassuring data helped the market rebound as retail sales rose above expectations, and the S&P 500 ended the month up by 2.4%. In terms of monetary policy, Federal Reserve Chair Jerome Powell signaled in the Jackson Hole meeting that a rate cut in September will be likely as inflation has continued to trend down to the central bank's 2.0% target. Outside of the US, the MSCI Europe Index returned 1.5%. Annual inflation fell from 2.9% in June to 2.1% in July, increasing the likelihood of another rate cut during the European Central Bank's September meeting. The Eurozone Composite and Services PMI remained in expansionary territory after the 2024 Olympic Games boosted business activity. Japanese equities experienced volatility in August after a sharp appreciation of the Yen versus the dollar triggered the month at -2.9%. The Japanese economy continues to grow supported by domestic demand as GDP growth grew by 0.8% in the second quarter. Emerging market equities posted positive returns with the MSCI Emerging Market Index returning 1.6% for the month as the US dollar weakened from Federal Reserve Chair Powell's dovish sentiment. The MSCI World Health Care returned 5.5% over the period. Within the index, all of the sectors rose over the month. Biopharma large cap and biopharma mid cap were the top performing sectors, while health care services and medical technology were the bottom performing sectors for the period.

**Fund Performance.** The fund returned 5.25% in August, lagging the benchmark by 24 basis points. Sector allocation, as a result of our bottom-up stock selection process, was the primary driver of relative underperformance. Allocation effect was driven by our out of benchmark allocation to biopharma small cap and underweight to biopharma large cap, but modestly offset by our underweight to medical technology. Stock selection, however, contributed to returns. Strong selection in biopharma large cap and health care services was partially offset by selection in biopharma mid cap.

**Fund Strategy.** Groundbreaking innovation, supportive valuations and business models positioned to show resilience through the cycle should benefit the sector over the long-term. Within the biopharma industry, breakthrough innovations continue to provide attractive opportunities. We remain selective in large-cap biopharma, avoiding companies with significant patent expirations and risk of future drug pricing pressure. Outside of biopharma, we believe medical technology innovation has never been stronger due to advancements in technology development, engineering capabilities and integrated informatics. Product cycles, procedure recovery, and biopharma innovation are creating investment opportunities. Within health care services, the fund favors companies focused on the societal challenge on improving patient outcomes while reining in costs. The fund will continue to favor companies that develop innovative products designed to address unmet medical needs. Over the long term, the tailwinds of innovation and an aging population should continue to drive growth for the sector.

## LIST OF PROSPECTIVE INVESTMENTS

The following are among the Fund's approved investment outlets, wherein the Trustee intends to invest depending on strategy, availability, or other market-driven circumstances:

- (a) Primarily in a single collective investment scheme whose investment objective is to provide investment results in excess of the return of the MSCI World Health Care Index; provided further that such CIS is approved or registered and supervised by a regulatory authority that is a member of the International Organization of Securities Commissions (IOSCO) and managed by reputable fund manager/s; provided further that the investment in the said collective investment scheme should at least be ninety percent (90%) of the total assets of the Fund. The Target Fund must be recognized as a collective investment scheme in its home jurisdiction by a regulatory authority or any regulatory authority acceptable to the BSP to supervise this CIS.
- (b) Short-term tradable fixed-income instruments issued or guaranteed by the Philippine government or the BSP; tradable securities issued by the government of a foreign country, any political subdivision/agency of a foreign country or any supranational entity; tradable fixed-income instruments issued by foreign or local financial institutions or private corporations; exchange- listed securities; marketable instruments that are traded in an organized exchange; loans traded in an organized market; and, such other tradable investments outlets/ categories as the BSP may allow. Provided, that, a financial instrument is regarded as tradable if two-way prices are quoted, readily available or regularly available from an exchange, dealer, broker, industry group, pricing service or regulatory agency, and those prices represent actual and regularly occurring market transactions on an arm's length basis.
- (c) Short-term tradable fixed-income instruments issued, underwritten, or otherwise dealt by BPI and/or any of its subsidiaries, affiliates, their successors-in-interest or assignees, their directors, officers, stockholders, and related interest, and any of their trust and fund managed accounts, under such terms and conditions as the Trustee may deem to be in the best interest of the Fund; and, any such other instruments as may be allowed under BSP regulations. Investment with related interests shall be in accordance with Section 414-Q of the Manual of Regulations for Non-Bank Financial Institutions.
- (d) The principal investments of the Fund will be denominated in, but not limited to the U.S. Dollar. The target fund invests in securities denominated in other currencies.
- (e) Bank deposits or tradable debt instruments issued by the BSP.

## INVESTMENT OBJECTIVE OF TARGET FUNDULations iss

The Wellington Global Health Care Equity Fund seeks long-term total returns. The Investment Manager will actively manage the Fund, seeking to achieve the objective by investing in the equity securities of health care companies worldwide. The Fund takes a long term value approach and seeks to invest in fundamentally sound companies. Although the Fund is not constructed relative to a benchmark, the MSCI World Health Care index will serve as a reference benchmark.

BPI Wealth is a subsidiary of the Bank of the Philippine Islands. For inquiries and comments, please send an email to bpiwealth@bpi.com.ph or call us at (632) 8580-2682.

BPI Wealth as Trustee/Investment Manager is regulated by the Bangko Sentral ng Pilipinas. https://www.bsp.gov.ph